tailieunhanh - Báo cáo khoa hoc:" Periodontal disease in a patient receiving Bevacizumab: a case report"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Periodontal disease in a patient receiving Bevacizumab: a case report | Journal of Medical Case Reports BioMed Central Case report Open Access Periodontal disease in a patient receiving Bevacizumab a case report Dorothy M Gujral Sanjeev Bhattacharyya Peter Hargreaves and Gary W Middleton Address St Lukes Cancer Centre Royal Surrey County Hospital Guildford UK Email Dorothy M Gujral - gjrdor001@ Sanjeev Bhattacharyya - sanjeev144@ Peter Hargreaves - Gary W Middleton - gmiddleton@ Corresponding author Published 13 February 2008 Received 12 October 2007 Journal of Medical Case Reports 2008 2 47 doi 1752-1947-2-47 Accepted 13 February 2008 This article is available from http content 2 1 47 2008 Gujral et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction Bevacizumab is a monoclonal antibody that inhibits the action of vascular endothelial growth factor VEGF thereby acting as an angiogenesis inhibitor. As a result supply of oxygen and nutrients to tissues is impaired and tumour cell growth is reduced. Reported side effects due to bevacizumab are hypertension and increased risk of bleeding. Bowel perforation has also been reported. Periodontal disease in patients on bevacizumab therapy has not been reported before. Case Presentation We report a case of a forty-three year old woman who developed periodontitis whilst receiving bevacizumab for lung cancer. The periodontal disease remained stable on discontinuation of the drug. Conclusion Further investigations are needed to determine the mechanism for bevacizumab-induced periodontal disease. Introduction Bevacizumab is a monoclonal antibody that inhibits the action of vascular endothelial growth factor VEGF thereby acting as an